Philipp von Rosenstiel

Author

Also Known As

Mahendra Bijarnia, P Rosenstiel, P von Rosenstiel, P. VON ROSENSTIEL, P. Von Rosenstiel, P. von Rosenstiel, P.V. Rosenstiel, Philipp Von Rosenstiel, Philipp von Rosenstiel

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)University Hospital of Basel Novartis (United States)Biogen (United States)Cleveland Clinic

About

Philipp von Rosenstiel is an author at Novartis (Switzerland) specializing in medicine, clinical trials, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	1.4K
2	Health Sciences	6	6	226
3	Endocrinology	3	3	274
4	Social Sciences	1	1	46
5	Epidemiology	1	1	14

Philipp von Rosenstiel

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin, The Lancet Neurology Disease ManagementRelapsing-remitting Multiple SclerosisDisease ProgressionNeurological DisorderClinical Trials	2014	815
Long-term effects of fingolimod in multiple sclerosis Ludwig Kappos, Paul O’Connor, Ernst‐Wilhelm Radue, Neurology	2015	187
Exacerbation of Apoptosis in the Dentate Gyrus of the Aged Rat by Dexamethasone and the Protective Role of Corticosterone Ali Hassan, Philipp von Rosenstiel, Vladimir K. Patchev, Experimental Neurology MedicinePhysiologyDentate GyrusNeuropharmacologyProtective Role	1996	179
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study Jeffrey A. Cohen, Bhupendra Khatri, Frederik Barkhof, Journal of Neurology Neurosurgery & Psychiatry	2015	162
Adjunctive brivaracetam for refractory partial-onset seizures Jacqueline A. French, Costantino Costantini, Alan L. Brodsky, Neurology	2010	151
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis Ludwig Kappos, Matthias Mehling, Rafael Arroyo, Neurology	2015	149
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis Ernst‐Wilhelm Radue, Frederik Barkhof, Ludwig Kappos, Neurology	2015	142
Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial‐onset seizures: A phase IIb, randomized, controlled trial Wim Van Paesschen, Édouard Hirsch, Martin Johnson, Epilepsia	2012	136
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings Ludwig Kappos, Jeffrey A. Cohen, William Collins, Multiple Sclerosis and Related Disorders Integrated AnalysisDisease ProgressionSafety FindingsMedicineNeurological Disorder	2014	117
Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. Samantha Budd Haeberlein, John O’Gorman, Ping-Chun Chiao, PubMed Amyloid βImmunologyNeurochemical BiomarkersAlzheimer's DiseaseEarly Alzheimer	2017	86

Page 1